122: The Impact of a Central Nervous System Event on Cognitive Function After Radiation Treatment in Patients With One-Ten Brain Metastases
Laura Beaton(BC Cancer Agency), Alan Nichol(BC Cancer Agency), François Germain(BC Cancer Agency), Hannah Carolan(BC Cancer Agency), Michael McKenzie(Provincial Health Services Authority), Robert Olson(BC Cancer Agency), Roy Ma(BC Cancer Agency), Arthur Cheung(BC Cancer Agency), Lovedeep Gondara(BC Cancer Agency), Devin Schellenberg(Surrey Place Centre), F.M. Hsu(University of British Columbia)
Cited by 0
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2017|319